{"id":69935,"date":"2026-07-14T14:40:30","date_gmt":"2026-07-14T06:40:30","guid":{"rendered":"https:\/\/flcube.com\/?p=69935"},"modified":"2026-07-14T14:40:31","modified_gmt":"2026-07-14T06:40:31","slug":"dizal-pharmaceutical-secures-1-5-billion-global-licensing-deal-with-astrazeneca-for-sunvozertinib-in-egfr-exon20ins-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69935","title":{"rendered":"Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Dizal Pharmaceutical Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/688192:SHA\">SHA: 688192<\/a>) announced a <strong>global licensing agreement<\/strong> with <strong>AstraZeneca plc<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/AZN:NYSE\">NYSE: AZN<\/a>), granting the British-Swedish pharmaceutical giant <strong>exclusive worldwide rights<\/strong> to develop and commercialize <strong>Sunvozertinib<\/strong>, an oral EGFR tyrosine kinase inhibitor for <strong>EGFR exon20 insertion mutation non-small cell lung cancer (NSCLC)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-transaction-financial-terms\" class=\"wp-block-heading\">Transaction Financial Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront Payment<\/strong><\/td><td>$600 million (one-time, non-refundable)<\/td><\/tr><tr><td><strong>Clinical Milestones<\/strong><\/td><td>Up to $400 million<\/td><\/tr><tr><td><strong>Sales Milestones<\/strong><\/td><td>Up to $500 million<\/td><\/tr><tr><td><strong>Total Potential Value<\/strong><\/td><td>$1.5 billion<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Tiered, up to low-double-digit percentage on global net sales<\/td><\/tr><tr><td><strong>Territory<\/strong><\/td><td>Global (exclusive)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>14 Jul 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-regulatory-status\" class=\"wp-block-heading\">Drug Profile &amp; Regulatory Status<\/h2>\n\n\n\n<h3 id=\"h-sunvozertinib-next-generation-egfr-tki\" class=\"wp-block-heading\">Sunvozertinib \u2013 Next-Generation EGFR TKI<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule Type:<\/strong> Oral, irreversible, highly selective EGFR tyrosine kinase inhibitor<\/li>\n\n\n\n<li><strong>Target:<\/strong> Multiple EGFR mutation subtypes, with focus on exon20 insertion mutations<\/li>\n\n\n\n<li><strong>Current Approvals:<\/strong><\/li>\n\n\n\n<li>China: Approved for locally advanced\/metastatic EGFR exon20ins NSCLC post-platinum chemotherapy<\/li>\n\n\n\n<li>United States: Approved for same indication<\/li>\n\n\n\n<li><strong>Pipeline Status:<\/strong> New drug applications under regulatory review for <strong>first-line treatment<\/strong> of EGFR exon20ins NSCLC in both China and U.S.<\/li>\n\n\n\n<li><strong>Differentiation:<\/strong> Designed to overcome limitations of earlier-generation EGFR inhibitors in exon20ins population<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-market-opportunity-context\" class=\"wp-block-heading\">Market Opportunity Context<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Patient Population:<\/strong> EGFR exon20 insertion mutations represent 4-10% of all EGFR-mutant NSCLC cases<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Historically poor response to conventional EGFR TKIs and limited treatment options<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Competes with amivantamab (Rybrevant) and mobocertinib (Exkivity) in the exon20ins space<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-implications\" class=\"wp-block-heading\">Strategic Rationale &amp; Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Stakeholder<\/th><th>Strategic Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Dizal Pharmaceutical<\/strong><\/td><td>Immediate cash infusion strengthens balance sheet; validates drug quality through AstraZeneca partnership; enables focus on other pipeline assets<\/td><\/tr><tr><td><strong>AstraZeneca<\/strong><\/td><td>Expands oncology portfolio in high-value EGFR mutation segment; leverages existing lung cancer commercial infrastructure; addresses growing exon20ins market<\/td><\/tr><tr><td><strong>Patients<\/strong><\/td><td>Enhanced global access to innovative therapy; potential acceleration of first-line approval timelines<\/td><\/tr><tr><td><strong>Investors<\/strong><\/td><td>De-risking of Dizal&#8217;s commercial execution risk; premium valuation validation for Chinese biotech innovation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The deal represents one of the largest outbound licensing transactions by a Chinese biopharmaceutical company, highlighting the maturing quality of China&#8217;s innovative drug development capabilities and their increasing acceptance by global pharmaceutical leaders.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-commercial-outlook\" class=\"wp-block-heading\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Revenue Trajectory:<\/strong> Analysts project peak annual sales of $800 million-$1.2 billion globally if first-line approvals are secured<\/li>\n\n\n\n<li><strong>Geographic Expansion:<\/strong> AstraZeneca&#8217;s established commercial presence in Europe, Japan, and emerging markets will accelerate international uptake<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Combination with AstraZeneca&#8217;s existing Tagrisso (osimertinib) franchise creates comprehensive EGFR mutation coverage<\/li>\n\n\n\n<li><strong>Valuation Impact:<\/strong> The $600 million upfront payment represents approximately 30% of Dizal&#8217;s current market capitalization, providing substantial financial flexibility<\/li>\n\n\n\n<li><strong>Industry Signal:<\/strong> Validates China&#8217;s capability to develop globally competitive targeted oncology therapies with novel mechanisms of action<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory approvals, commercial performance, and strategic benefits of the Dizal-AstraZeneca collaboration. Actual results may differ due to risks including regulatory decisions, competitive dynamics, market adoption rates, and clinical trial outcomes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688192_20260714_LOKU.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688192_20260714_LOKU.\"><\/object><a id=\"wp-block-file--media-aa5fefa2-9d7f-4879-b8ce-96bfbb3e488c\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688192_20260714_LOKU.pdf\">688192_20260714_LOKU<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/688192_20260714_LOKU.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-aa5fefa2-9d7f-4879-b8ce-96bfbb3e488c\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced a global licensing agreement with AstraZeneca plc (NYSE:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[130,16,191,4621,981,33],"class_list":["post-69935","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-astrazeneca","tag-cancer","tag-dizal-pharmaceutical","tag-nyse-azn","tag-sha-688192","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced a global licensing agreement with AstraZeneca plc (NYSE: AZN), granting the British-Swedish pharmaceutical giant exclusive worldwide rights to develop and commercialize Sunvozertinib, an oral EGFR tyrosine kinase inhibitor for EGFR exon20 insertion mutation non-small cell lung cancer (NSCLC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69935\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC\" \/>\n<meta property=\"og:description\" content=\"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced a global licensing agreement with AstraZeneca plc (NYSE: AZN), granting the British-Swedish pharmaceutical giant exclusive worldwide rights to develop and commercialize Sunvozertinib, an oral EGFR tyrosine kinase inhibitor for EGFR exon20 insertion mutation non-small cell lung cancer (NSCLC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69935\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-14T06:40:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-14T06:40:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69935#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69935\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC\",\"datePublished\":\"2026-07-14T06:40:30+00:00\",\"dateModified\":\"2026-07-14T06:40:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69935\"},\"wordCount\":472,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"AstraZeneca\",\"Cancer\",\"Dizal Pharmaceutical\",\"NYSE:\u202fAZN\",\"SHA: 688192\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69935#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69935\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69935\",\"name\":\"Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-14T06:40:30+00:00\",\"dateModified\":\"2026-07-14T06:40:31+00:00\",\"description\":\"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced a global licensing agreement with AstraZeneca plc (NYSE: AZN), granting the British-Swedish pharmaceutical giant exclusive worldwide rights to develop and commercialize Sunvozertinib, an oral EGFR tyrosine kinase inhibitor for EGFR exon20 insertion mutation non-small cell lung cancer (NSCLC).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69935#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69935\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69935#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC - Insight, China&#039;s Pharmaceutical Industry","description":"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced a global licensing agreement with AstraZeneca plc (NYSE: AZN), granting the British-Swedish pharmaceutical giant exclusive worldwide rights to develop and commercialize Sunvozertinib, an oral EGFR tyrosine kinase inhibitor for EGFR exon20 insertion mutation non-small cell lung cancer (NSCLC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69935","og_locale":"en_US","og_type":"article","og_title":"Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC","og_description":"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced a global licensing agreement with AstraZeneca plc (NYSE: AZN), granting the British-Swedish pharmaceutical giant exclusive worldwide rights to develop and commercialize Sunvozertinib, an oral EGFR tyrosine kinase inhibitor for EGFR exon20 insertion mutation non-small cell lung cancer (NSCLC).","og_url":"https:\/\/flcube.com\/?p=69935","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-14T06:40:30+00:00","article_modified_time":"2026-07-14T06:40:31+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69935#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69935"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC","datePublished":"2026-07-14T06:40:30+00:00","dateModified":"2026-07-14T06:40:31+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69935"},"wordCount":472,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["AstraZeneca","Cancer","Dizal Pharmaceutical","NYSE:\u202fAZN","SHA: 688192","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69935#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69935","url":"https:\/\/flcube.com\/?p=69935","name":"Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-14T06:40:30+00:00","dateModified":"2026-07-14T06:40:31+00:00","description":"Dizal Pharmaceutical Co., Ltd. (SHA: 688192) announced a global licensing agreement with AstraZeneca plc (NYSE: AZN), granting the British-Swedish pharmaceutical giant exclusive worldwide rights to develop and commercialize Sunvozertinib, an oral EGFR tyrosine kinase inhibitor for EGFR exon20 insertion mutation non-small cell lung cancer (NSCLC).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69935#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69935"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69935#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Dizal Pharmaceutical Secures $1.5 Billion Global Licensing Deal with AstraZeneca for Sunvozertinib in EGFR Exon20ins NSCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69935","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69935"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69935\/revisions"}],"predecessor-version":[{"id":69937,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69935\/revisions\/69937"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69935"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69935"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69935"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}